Skip to main content
Jafron Biomedical Co.,Ltd. logo

Jafron Biomedical Co.,Ltd. — Investor Relations & Filings

Ticker · 300529 ISIN · CNE100002995 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,842 across all filing types
Latest filing 2023-06-02 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300529

About Jafron Biomedical Co.,Ltd.

https://www.jafron.com

Jafron Biomedical Co.,Ltd. specializes in the research, development, and manufacturing of biomaterials and equipment for blood purification. The company is a primary provider of hemoperfusion technology, focusing on the production of adsorbent cartridges designed to remove specific toxins and inflammatory mediators from the bloodstream. Its core product portfolio includes the HA series of hemoperfusion cartridges, which are applied in clinical settings for end-stage renal disease, acute poisoning, critical care, and liver failure. Beyond consumables, the company develops blood purification machines and integrated treatment systems. These solutions target clinical applications in nephrology, intensive care, and hepatology. By leveraging advanced resin adsorption technology, the company provides specialized extracorporeal blood treatment options aimed at improving patient outcomes in complex medical conditions.

Recent filings

Filing Released Lang Actions
职工代表大会会议决议公告
Regulatory Filings Classification · 95% confidence The document is a meeting resolution announcement from the employee representative meeting of the company, discussing approval of an employee stock ownership plan draft. It mentions compliance with company law and securities law, and states that the plan still requires approval by the board and shareholders. The document is short (609 characters) and is an announcement of a meeting decision rather than a full report or financial statement. It does not contain financial data or detailed report content. This fits best with a Regulatory Filing (RNS) as it is a general regulatory announcement about corporate governance matters and employee stock plans, not a full governance report or management report.
2023-06-02 Chinese
第五届监事会第三次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of resolutions passed at the third meeting of the fifth Supervisory Board of the company. It details the meeting attendance, the approval of employee stock ownership plan proposals, and voting results. It references that the detailed plans are disclosed elsewhere on a regulatory website. The document is short (1266 characters) and serves as an official meeting resolution announcement rather than a full report or detailed financial disclosure. It does not contain financial statements or detailed management discussion. It is not a report publication announcement since it contains substantive meeting resolution content. The document fits best under Regulatory Filings (RNS) as a general regulatory announcement of supervisory board meeting resolutions and related approvals, which do not fit other more specific categories.
2023-06-02 Chinese
公司章程（2023年6月）
Governance Information Classification · 100% confidence The document is titled as the Articles of Association (章程) of 健帆生物科技集团股份有限公司 dated June 2023. It contains detailed provisions about the company's organization, shareholder rights, board structure, share issuance, shareholder meetings, and other governance matters. It is a legal and governance document that sets out the internal rules and regulations of the company. There is no indication that this is an annual report, financial report, or any other type of report. It is not a notice or announcement but the actual governance charter of the company. Therefore, the document fits the category of Governance Information (CGR). The document length is substantial and contains detailed governance content, confirming it is not a brief announcement or a report publication notice.
2023-06-02 Chinese
独立董事关于第五届董事会第三次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from the independent directors of a company regarding an employee stock ownership plan and its management measures. It references compliance with relevant laws and regulations, and it is dated June 2, 2023. The content focuses on governance and approval of internal company plans rather than financial results, audit opinions, or shareholder voting results. It does not contain financial statements or earnings data, nor is it a simple announcement of a report. The document is related to board-level governance and management decisions about employee incentive plans, which fits best under Board/Management Information (MANG).
2023-06-02 Chinese
监事会关于公司奋斗者二号员工持股计划相关事项的审核意见
Board/Management Information Classification · 90% confidence The document is a supervisory board's review opinion on the company's employee stock ownership plan, referencing compliance with company law, securities law, and regulatory guidelines. It discusses the legality, approval process, and benefits of the employee stock ownership plan, and mentions submission to the shareholders' meeting for approval. The document is a formal opinion or review related to governance and employee incentive plans, not a financial report, earnings release, or capital update. It does not contain financial statements or results, nor is it a notice of voting results or a proxy solicitation. It fits best under Board/Management Information (MANG) as it relates to management-level decisions and governance matters regarding employee stock plans.
2023-06-02 Chinese
国浩律师（深圳）事务所关于公司实施员工持股计划之法律意见书
Audit Report / Information Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the implementation of an employee stock ownership plan by a listed company. It extensively discusses the legal compliance, procedures, and regulatory adherence related to the employee stock ownership plan. It is not a financial report, earnings release, or management discussion, nor is it a regulatory announcement or proxy solicitation. The document is a standalone legal opinion related to a specific corporate action (employee stock ownership plan). This fits best under the category of Audit Report / Information (AR), as it is a specialized legal audit/opinion on a corporate governance and compliance matter, not a full annual report or other categories. The document length and content confirm it is a full legal opinion, not just an announcement or certification, so it is not RNS or RPA. Therefore, the classification is AR with high confidence. FY 2023
2023-06-02 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.